<span item_type="fundamental" item_id="6a3a38c835e5ac4d1b19188a0d4f44c3" counter_id="ST/US/HSCSW" env="prod"></span><span item_type="announcement" item_id="541831663149981569" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 4 K.</p><p>EPS: As of FY2025, the actual value is USD -9.34.</p><p>EBIT: As of FY2025, the actual value is USD -8.353 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Revenue for the year ended April 30, 2025 was $4,000, compared to $19,000 for the year ended April 30, 2024, representing a decrease of 79%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000095017025098326/hscs-20250430.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the year ended April 30, 2025 was $8.8 million, compared to $6.6 million for the year ended April 30, 2024, representing an increase of 33%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000095017025098326/hscs-20250430.htm"></span></li><li><strong>Gross Margin</strong>: Gross margin for the year ended April 30, 2025 was $2,000, compared to $13,000 for the year ended April 30, 2024, representing a decrease of 85%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000095017025098326/hscs-20250430.htm"></span></li><li><strong>Research and Development Expenses</strong>: R&amp;D expenses for the year ended April 30, 2025 were $4.4 million, compared to $2.9 million for the year ended April 30, 2024, representing an increase of 52%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000095017025098326/hscs-20250430.htm"></span></li><li><strong>Selling, General and Administrative Expenses</strong>: Selling, general, and administrative expenses for the year ended April 30, 2025 were $3.9 million, compared to $3.4 million for the year ended April 30, 2024, representing an increase of 15%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000095017025098326/hscs-20250430.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities for the year ended April 30, 2025 was $7.4 million, compared to $6.1 million for the year ended April 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000095017025098326/hscs-20250430.htm"></span></li><li><strong>Free Cash Flow</strong>: Net cash used in investing activities for the year ended April 30, 2025 was $30,000, compared to $125,000 for the year ended April 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000095017025098326/hscs-20250430.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Debt Financing</strong>: The Company issued an unsecured note in the original principal amount of $2,510,000 to Streeterville Capital, LLC, with net proceeds of approximately $1.9 million after original issue discount and transaction expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000095017025098326/hscs-20250430.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The Company plans to continue devoting significant capital resources to R&amp;D, clinical studies, and go-to-market strategies. Additional funding will be required to support the sales launch of its products into the U.S., provide working capital, and support further R&amp;D.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000095017025098326/hscs-20250430.htm"></span></li></ul>

HEARTSCIENCES INC C/WTS (TO PUR COM) | 10-K: FY2025 Revenue: USD 4 K